According to Biocon and Mylan, their respective breast

cancer medications are prescribed only for metastatic breast cancer, as a single judge bench of the high court had on August 13, 2015, restrained them from selling their respective Trastuzumab medicines for early breast cancer and metastatic gastric cancer.

However, both companies claim to have approvals from DCGI to sell their respective medicines for the other two cancers also, a decision which has been challenged by Roche in its civil suit claiming "passing off" of its breast cancer drugs by the two companies.

Biocon and Mylan have taken the stand that Roche no longer holds a patent in India for Trastuzumab.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)